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ABSTRACT 
INTRODUCTION: Internationally, non-medical practitioners are increasingly involved in tasks tradition-
ally undertaken by general practitioners (GPs), such as medication review and prescribing. This study 
aims to evaluate GPs’ perceptions of pharmacists’ contributions to those services. 
METHODS: Semi-structured interviews were carried out in two localities with GPs whose patients had 
and had not undergone a pharmacist-led adherence support Medication Use Review (MUR). GPs were 
asked their opinions of pharmacists’ provision of MUR, clinical medication review and prescribing. Data 
were analysed thematically using NVivo 8 and grouped by strengths, weaknesses, opportunities and 
threats (SWOT) category. 
FINDINGS: Eighteen GPs were interviewed. GPs mentioned their own skills, training and knowledge 
of clinical conditions. These were considered GPs’ major strengths. GPs’ perceived weaknesses were 
their time constraints and heavy workloads. GPs thought pharmacists’ strengths were their knowledge 
of pharmacology and having more time for in-depth medication review than GPs. Nevertheless, GPs 
felt pharmacist-led medication reviews might confuse patients, and increase GP workloads. GPs were 
concerned that pharmacist prescribing might include pharmacists making a diagnosis. This is not the pro-
posed model for New Zealand. In general, GPs were more accepting of pharmacists providing medication 
reviews than of pharmacist prescribing, unless appropriate controls, close collaboration and co-location 
of services took place. 
CONCLUSION: GPs perceived their own skills were well suited to reviewing medication and prescribing, 
but thought pharmacists might also have strengths and skills in these areas. In future, GPs thought that 
working together with pharmacists in these services might be possible in a collaborative setting.
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Introduction
Two traditional tasks for general practitioners 
(GPs) are prescribing and reviewing patients’ 
medications. When performing these tasks doc-
tors are expected to discuss and reach an agree-
ment with their patients regarding the medica-
tions they plan to prescribe.1
In some countries, other health professionals 
may also be involved in these tasks. In Australia, 
pharmacists are authorised to conduct medication 
reviews known as Home Medication Reviews 
(HMRs).2 Although pharmacists are not yet 
permitted to prescribe, other health professionals 
in Australia, such as nurse practitioners, podia-
trists and optometrists are authorised to prescribe 
within their scopes of practice.3 In contrast to 
Australia, pharmacists in England were granted 
supplementary prescribing rights in 2003 and, in 
2006, independent prescribing rights as part of 
a medical team.4 Pharmacist prescriber roles are 
also present in certain states in the United States 
of America and Canada.5,6 In these countries, 
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pharmacists are also authorised to conduct medi-
cines management for patients.7–9
The introduction of prescribing by non-medical 
health professionals has been the subject of much 
debate. Doctors whose patients have experienced 
nurse prescribing perceived the service to have a 
positive impact on patient care as it reduced pa-
tients’ waiting time for prescriptions and patients 
were provided with more detailed information 
about their medications.10,11 However, GPs felt 
that the clinical skills required for prescribing 
should not be underestimated,12 that nurses had 
limited skills, and that extra skills—such as 
physical assessment and diagnosis—are required 
before prescribing.11–13 Similar mixed responses 
were reported by GPs for pharmacist prescrib-
ing.14 GPs felt that to be acknowledged as pre-
scribers, pharmacists would need to demonstrate 
their expertise and already be known to the GP 
practice.15 GPs were also concerned about pharma-
cists’ level of training and skills in diagnosis and 
that prescribing was perceived to occur subse-
quently to pharmacists making a diagnosis.14–16 
Pharmacists in New Zealand (NZ) are also extend-
ing their roles. As part of the NZ National Phar-
macy Services Framework 2007, some pharmacists 
have been contracted to provide Medication Use 
Review (MUR) and adherence support services 
on a fee-for-service basis.17 In addition, a more in-
depth review termed Medicines Therapy Assess-
ment (MTA) is currently being trialled in some 
areas in NZ. MTA is similar to Clinical Medica-
tion Review in the UK18 that aims to optimise a 
patient’s medication in the context of the clinical 
picture. Pharmacist prescribing, a proposed ser-
vice, aims to optimise patients’ access to medica-
tions and help achieve desired treatment goals.19
Pharmacist prescribing is intended to occur in 
close collaboration with a medical practitioner 
(e.g. a GP). In this setting, the medical practition-
er would be responsible for diagnosis, selection of 
treatment modality (e.g. medication) and set-
ting treatment goals. The accredited pharmacist 
would then initiate/modify medication therapy 
to optimise attainment of those goals.19 The term 
‘collaboration’ in the proposed scope of pharma-
cist prescribing in NZ means that pharmacist pre-
scribers are required to practise in a health team 
environment where patients are the main focus 
of collaboration and patient information is shared 
among the health care team members. This does 
not have the same meaning as ‘collaborative 
prescribing’, also known as ‘dependent prescrib-
ing’ as defined in the UK, that describes a model 
that requires medical prescribers to authorise 
pharmacists’ prescribing practice. The NZ model 
for pharmacist prescribing is the same as for 
existing prescribers which is that of ‘independent 
prescribing’. It does not require pharmacists to 
have delegated authority from medical prescribers 
and pharmacists are legally and independently 
responsible and accountable for their prescrib-
ing decisions. Hence, NZ pharmacists would be 
independent prescribers and would work col-
laboratively.19
An earlier study in NZ, conducted between 2002 
and 2004, examined GPs’ perceptions of proposed 
clinical roles for pharmacists.20,21 It was reported 
that GPs were less accepting of, and were con-
cerned about, pharmacists’ clinical roles20 and 
their value for patients and GPs.21 In the light 
of the new framework for pharmacy services in 
2007 and recent proposals for pharmacist pre-
scribing, more information on GPs’ perceptions of 
pharmacists’ skills and competence in medication 
review and prescribing are needed. This study 
therefore aims to explore GPs’ perceptions of 
pharmacists’ current and potential contributions 
to those services in NZ. 
Methods
This study was conducted as qualitative semi-
structured interviews with three groups of GPs 
in two localities in NZ. The two localities were 
in urban areas of two cities. These locations were 
chosen based on available information about 
pharmacists providing MUR.17 Ethical approval 
was obtained from the Human and Ethics Com-
mittee, University of Otago (Ref. F10/008).
GPs were invited initially by mail and after a 
week, if there was no reply, a follow-up phone 
call was made. The interviews were conducted by 
EH who has a pharmacy background and, prior 
to the interview, GPs were informed of this fact. 
The present study focused on GPs’ perceptions of 
pharmacists’ contributions to medication reviews 
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WHAT GAP THIS FILLS 
What we already know: An earlier study in New Zealand reported 
concerns from general practitioners regarding pharmacists’ clinical roles in 
performing medication reviews. Currently pharmacists in some parts of New 
Zealand are funded to provide medication reviews and a further proposed 
service is pharmacist prescribing. 
What this study adds: GPs perceived that pharmacist prescribing would 
include pharmacists making a diagnosis. This is different from the proposed 
model for pharmacist prescribing that is reliant on a medical practitioner’s 
diagnosis and treatment plan. In general, the current study found general 
practitioners to be more accepting of pharmacists providing medication 
reviews and reluctant to accept pharmacist prescribing unless appropriate 
controls with close collaboration and co-location of services occurred. 
and prescribing and the potential impact on 
patients and on GPs’ own daily practice. GPs from 
location one were GPs who did not have patients 
who had undergone an MUR by their community 
pharmacist and were selected using a combina-
tion of purposive and convenience sampling 
techniques, as described by Marshall.22 GPs were 
approached purposively according to their years of 
practice. GPs were divided into two groups—GPs 
with less than 20 years’ experience as a medical 
practitioner (Group one—G1) and GPs with 20 or 
more years’ experience as a medical practitioner 
(Group two—G2). GPs with differing years of 
experience were considered in this study, as this 
factor was reported in other studies to have a 
significant influence on GPs’ perceptions.23,24 Par-
ticipants were also selected to achieve an appropri-
ate balance of gender. G1 and G2 were identified 
from the local telephone directory and their years 
of practice were identified from the New Zealand 
Medical Council website.25 A total of 44 GPs 
were purposively invited to participate in the 
study. Participation in the study was voluntary 
and GPs were informed that they could withdraw 
from the study at any time without any disadvan-
tage to themselves or their practice. No incentives 
were offered to participants in this study.
GPs from location two, Group three (G3), were 
GPs whose patients had undergone an MUR by 
their local community pharmacist. GPs were 
identified by convenience sampling—by contact-
ing the community pharmacists who had partici-
pated in the previous MUR study conducted by 
the School of Pharmacy, University of Otago.17 
Pharmacists were asked to suggest GPs who 
had patients who had participated in the MUR 
services and all GPs (n=29) that were named were 
invited to participate in this study. Due to a lim-
ited sample, further division according to years of 
practice in this group was not considered.
Each 30-minute interview was conducted face-
to-face at the GP’s surgery. The interviews were 
tape-recorded with agreement from the GPs. The 
themes of the interview questions were devel-
oped through a literature review of previously 
published qualitative studies26–30 and discussion 
among the authors of the current study. The 
questionnaire was then piloted by a GP and two 
registered pharmacists who were familiar with 
the services provided by community pharmacists. 
The input from the pilot interviews was used to 
further refine the interview topics. The interview 
schema was developed in such a way as to ensure 
the theoretical and conceptual understanding of 
the research topics was well established.31 GPs 
were asked about how they perceived pharmacists 
providing medication review and prescribing. The 
topic guide used for asking questions during the 
interviews is shown in full in Appendix 1 (see 
the web version of the paper). Prior to the inter-
view, brief descriptions of pharmacist services 
were given to the GPs (Table 1). 
The interviews were transcribed verbatim and 
sensitive information was removed to ensure con-
fidentiality. Transcription accuracy was checked 
by an independent third party. To ensure the va-
lidity of coding and that saturation was achieved, 
a second investigator read and coded every third 
and last transcription from each group, using the 
finalised code structure independently.32 Any dis-
agreement was resolved through consensus. Data 
collection was ceased when no new themes were 
found in at least two consecutive interviews.
GPs’ perceptions were examined using thematic 
analysis and constant comparison33 with NVivo 8 
software. A strengths, weaknesses, opportuni-
ties and threats (SWOT) process—a tool used 
in organisational planning—was utilised in the 
analysis to classify the themes into internal and 
external factors that have the potential to influ-
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ence success or failure, in this case of medication 
review and prescribing services.34 This tool has 
been used commonly in business to generate 
strategic planning or an action plan, to achieve 
the company’s objective or help with decision-
making.35 In this study, the SWOT analysis was 
used to provide the framework for analysing the 
strengths and weaknesses (internal factors) and 
opportunities and threats (external factors) for 
GPs’ practice associated with medication-related 
services to patients. The themes identified were 
examined using comparative analysis between the 
groups (groups 1–3) for similarity and differences 
in perceptions.32
Findings
Eighteen GPs agreed to participate in this study 
and saturation of themes was achieved within 
this number. Participants’ demographics are pre-
sented in Table 2. Common themes that emerged 
from the interviews with regard to medication 
review and prescribing were grouped according to 
GPs’ perceptions of the strengths and weaknesses 
of GPs and pharmacists (Table 3), and potential 
opportunities and threats to GPs’ daily prac-
tice (Table 4). Although we did not specifically 
ask GPs about their perceptions of their own 
contributions (e.g. strengths and weaknesses) to 
medication review and prescribing, these themes 
were raised frequently during the interviews. 
GPs’ perceptions were also compared between the 
groups (groups 1, 2 and 3) and the same themes 
were found to be raised in each group.
GPs’ views of their own 
strengths and weaknesses
GPs considered their own strengths to be their 
skills and training in diagnosis and treatment, 
Table 2. Demographic data of the respondents
Groups
GPs with no MUR patients* 
(Location 1)
GPs with MUR 
patients* 
(Location 2)
Group 3 
Group 1 
(<20 years experience) 
Group 2 
(≥20 years experience)
Number (n) 7 6 5
Gender
Male
Female
2
5
3
3
3
2
Mean years of experience
(range)
13.5 
(6–19)
28.5 
(22–34)
27.8 
(15–37)
Average number of 
patients seen in a week 
(range)
80
(60–105)
98
(50–160)
124 
(20–250)
Average pro-rata FTE 
(range)
0.7
0.5–1.0
0.8
0.5–1.5
1.0
0.2–1.6
FTE  full-time equivalent
*  MUR patients are patients who have had a medication use review (MUR) by a pharmacist
Table 1. Brief descriptions of pharmacist services given to participants
Service Description
Medication Use Review 
(MUR)
This is a patient-centred service. A pharmacist reviews 
the patient’s medications, both prescribed and purchased 
for self-medication, and identifies any problems related 
to medication use, such as administration techniques 
(e.g. inhaler use) or non-adherence. While providing 
this service, a pharmacist will educate patients about 
their medications and help to improve patient adherence 
to medications. A pharmacist may produce a complete 
medication list for reference.
Clinical Medication 
Review 
These services involve a patient-centred medication 
review aimed at optimising the choice and use of 
medications with regard to appropriateness, effectiveness 
and safety. To provide this service, pharmacists need 
to have access to patients’ clinical notes. This service is 
provided as a fully integrated process with the prescriber 
(e.g. located in a GP’s practice). This service will also 
include adherence support (an MUR).
Pharmacist prescribing  In this study, note that GPs were not given a detailed 
explanation of what was meant by pharmacist 
prescribing. This was in order to get a GP’s personal 
impression about pharmacist prescribing in general (e.g. 
for prescribing over-the-counter medications, prescribing 
for repeat prescriptions, and prescribing collaboratively 
with GPs). 
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Table 3. General practitioners’ views of their own and pharmacists’ strengths and weaknesses in medication review and prescribing
Medication-related 
services
GPs’ perceived 
strengths
GPs’ perceived 
weaknesses 
Pharmacists’ perceived 
strengths 
Pharmacists’ perceived 
weaknesses
MUR Know patients’ clinical 
conditions well
Provide medications advice 
to patients
Lack of time 
Heavy workload
Pharmacists’ knowledge 
of pharmacology and drug 
interactions 
Longer consultation time
Funded to provide the 
service 
Strategic place for 
medication counselling  
(with the presence of 
patients’ medications)
Could get more information 
of how patients use their 
medications
Do not know the patients’ 
clinical conditions well
Limited source of patient 
information 
Clinical Medication 
Review
Strong set of skills
Know patients’ clinical 
conditions well
Provide brief medication 
reviews to patients
Lack of time for in-depth 
medication reviews
Limited knowledge of  
pharmacology and drug 
interactions
Lack of time 
Heavy workload
Good level of knowledge 
of pharmacology and drug 
interactions
Longer consultation time
Funded to provide the 
service
Do not know the patients’ 
clinical conditions well
Appropriate skills?
Limited source of patient 
information
Prescribing Strong set of skills 
Know patients’ clinical 
conditions well
Directed by guidelines
Regular component of work
Lack of time
Heavy workload 
Pharmacists’ knowledge 
of pharmacology and drug 
interactions
Do not know the patients’ 
clinical conditions well
Appropriate skills?
 Limited source of patient 
information
GP general practitioner; MUR medication use review
and their knowledge of clinical conditions. They 
thought they knew their patients’ clinical condi-
tions well, and understood the usual processes of 
care. Another perceived strength was GPs’ ability 
to practise according to guidelines. 
Part of my training is to use all that I have… the 
talking, the examination, the history to formulate 
what’s going on. I’m not convinced that pharmacists 
or nurses have that background. (GP#6, G2)
When hearing about pharmacist-led clinical 
medication review, a number of GPs said they al-
ready reviewed patients’ medication—that is, they 
provided brief medication reviews and advice 
to patients. They thought this would be similar 
to the pharmacists’ proposed services but was 
perhaps not as in-depth as the services described 
to them. 
GPs thought their own weaknesses were the lim-
ited time to conduct medication reviews, heavy 
workloads and limited knowledge of pharmacol-
ogy and drug interactions. They thought it was 
quite difficult to talk about medication issues or 
do a detailed check for drug interactions during a 
15-minute consultation. 
I think that in general, general practitioners gener-
ally feel that there’s more work than they can do 
and that they often try and cram work in and often 
aren’t allowing things the time that they should. 
(GP#10, G1)
I don’t think pharmacology is a strong point with 
GPs. I don’t think it’s well taught … in med schools. 
So having feedback about any potential [interac-
tions]… will be really fortunate. (GP#10, G1) 
[Speaking about Clinical Medication Review]
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GPs’ views of pharmacists’ 
strengths and weaknesses 
GPs thought that pharmacists’ strengths were 
their knowledge of pharmacology and drug in-
teractions, and a better knowledge about aspects, 
such as dosage forms and the appearance of 
medications. GPs also thought pharmacists had a 
better knowledge of herbal and alternative prepa-
rations than GPs. Another strength perceived was 
that pharmacists would have a longer consulta-
tion time if funded by the health system to talk 
about medication use with patients. 
I don’t think it’s possible for us to have some of the 
skill set that the pharmacists do. Pharmacists have 
specialist knowledge in some aspects of medication 
or you might say all aspects… so if somehow com-
bining the two so that we work together and utilise 
everybody’s skill set… (GP#11, G1)
GPs perceived a pharmacy-based setting with the 
presence of patients’ medications would enhance 
the counselling process. Another perceived 
strength would be pharmacists’ ability to obtain 
in-depth, medication-focused information from 
patients. GPs thought patients might have barri-
ers to sharing their medication issues with GPs 
because patients might not feel confident to tell 
their doctor that they were unhappy with the 
treatment prescribed.
Perceived pharmacists’ weaknesses included a lack 
of knowledge about each patient’s medical history 
and clinical conditions. Pharmacists were also 
thought to lack the appropriate skills to prescribe 
or review patients’ medications clinically. Some 
patients’ unfavourable experiences with pharma-
cists’ advice on over-the-counter medications had 
raised GPs’ doubts about pharmacists’ clinical 
skills. GPs also felt that a pharmacy might not be 
an appropriate setting for discussing confidential 
issues with patients.
It’s okay I mean I suppose my only reservation is that 
if you [pharmacists] don’t have all the information 
from the clinical examination before examination, 
then it’s not always easy to work out what’s appro-
priate if you’ve only got a history to go by. (GP#5, 
G1) [Speaking about Clinical Medication Review]
Table 4. General practitioners’ views of opportunities and threats ensuing from pharmacists’ contribution in medication-related services
Medication-related services 
if provided by pharmacists
Opportunities perceived by GPs Threats perceived by GPs
MUR Increase patients’ understanding of medication used
Increase adherence to medications
Simplify patients’ drug regimen
Source for GPs for drug information
Will be an additional source of information on the 
patients for the GPs
May confuse the patient 
May interfere with GP–patient relationship
Operational challenges for GPs (e.g. increase workload 
and time)
No remuneration for GPs’ additional work
Clinical Medication Review Ensure patients use medications safely
Checking for prescribing errors and interactions
Can help to optimise medication effectiveness
Source for GPs for drug information 
May conflict with other recommendations
May confuse the patient 
May harm the patient
Confidentiality issues with patients’ notes
Operational challenges for GPs
No remuneration for GPs’ additional work
Pharmacist prescribing Improve access to medications
Reduce GPs’ workloads
Checking for drug interactions
Fragmented patient care
Discontinuity of care
Conflict with pharmacists’ business interests 
May harm the patient
Operational challenges for GPs 
Competition for work with GPs
GP general practitioner; MUR medication use review
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I think it depends on what the condition is and how 
well the pharmacist has trained as a diagnostician…
I’m not convinced that pharmacists or nurses have 
that background. (GP#6, G2) [Speaking about 
pharmacist prescribing]
To be honest, the one thing that I don’t think they 
[pharmacists] do that well, is actually dispense 
over the counter medications. But, I probably get a 
completely false idea, because I see all the people 
whose over-the-counter medications have failed 
them. (GP#4, G3) [Speaking about dispensing over-
the-counter medications]
GPs’ views of possible opportunities 
for pharmacist contributions
GPs mentioned some opportunities for pharma-
cist contributions. GPs thought that pharmacists’ 
greater knowledge of pharmacology and dosage 
forms, adverse drug effects and drug interactions 
would be an asset in helping ensure patient safety. 
They thought that a clinical medication review by 
pharmacists might reduce prescribing errors and 
provide reassurance of correct prescribing. Phar-
macists’ up-to-date knowledge of pharma  cology 
was also thought an advantage as they could help 
to optimise patients’ medication and be a source 
of medications information for GPs. 
They [pharmacists] are an invaluable back-up be-
cause GPs do make prescribing errors and to know 
it’s a blanket that… if you write something stupid 
there’s somebody else checking it… that they make 
sure that no harm comes to the patient. (GP#10, G1) 
[Speaking about Clinical Medication Review]
It will be quite good to have a community pharma-
cist that visits GP practices and gives some input 
into some of the complicated drug regimen patients. 
Not necessarily just from the local pharmacy, but 
maybe someone that is more clinically orientated 
and has experience in that area... you know [see the] 
polypharmacy type of patients. (GP#3, G2)  
[Speaking about Clinical Medication Review]
GPs said pharmacists would have an advantage 
over GPs with regard to consultation time, as 
in-depth medication reviews are difficult and 
time-consuming. Furthermore, GPs thought 
pharmacists could notify the GP about a patient’s 
medication-related problems that the GP might 
be unaware of. They thought such services could 
also increase patients’ understanding and adher-
ence to medications.
It [an MUR] will tell us what the patient is taking… 
in terms of OTC [over-the-counter] medication 
and alternative medication. It might also inform us 
what they are not actually taking, but we prescrib-
ers [are] thinking that they are taking it so… it 
might give us an idea of compliance and so there ul-
timately might be cost-benefits and safety benefits. 
(GP#1, G2) [Speaking about MUR]
Well my recollection [for MUR] is that there were 
one or two things that the pharmacist pointed out 
that could be changed for the patient’s benefit. 
(GP#3, G3) [Speaking about MUR]
Many GPs thought pharmacists might have a 
limited role in prescribing. Prescribing under 
agreed protocols or guidelines (for a limited num-
ber of diseases and conditions), with appropriate 
training and close monitoring was more accept-
able to GPs. In addition, pharmacist prescrib-
ing for patients with warfarin was perceived as 
potentially beneficial by some as it could reduce 
GPs’ and nurses’ workloads. However, GPs would 
prefer this to happen within the GP’s practice, 
as it could improve communication and prevent 
information being ‘lost in transfer’. It would also 
allow GPs to have more control over decisions on 
patients’ medications.  
For us being able to spread things out to nurse pre-
scribing here was like a burden was lifted from us. 
So I think it’s great. (GP#10, G1) [Speaking about col-
laborative prescribing for patients taking warfarin] 
I guess if we are seeing them from time to time, 
to have the ability to say ‘Well no, actually this is 
getting a little bit unsafe and now you need to…
just to see us for it, would be appropriate. (GP#10, 
G1) [Speaking about collaborative prescribing for 
patients taking warfarin]
GPs’ views of the possible threats 
of pharmacist contributions 
Some GPs thought that pharmacists’ contribu-
tions to medication reviews might be a threat 
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to patient care, as the advice provided could 
conflict with that given by the GP (e.g. about a 
clinically irrelevant drug interaction) and hence 
might confuse patients and harm GP–patient 
relationships. 
I would not want to refer patients to the pharma-
cist for review only to find that the patient comes 
back and tells me that I shouldn’t have done this, I 
shouldn’t have done that. So it’s a relationship that 
could be undermined by the pharmacist if they’re 
not careful what they’re saying. (GP#3, G3)
GPs thought that if prescribing were undertaken 
outside the GPs’ surgery, and without close 
communication, this could fragment patient 
care, reduce the frequency of GPs seeing their 
patients, and decrease their opportunities to talk 
with their patients about other health concerns. 
GPs were also worried that those services could 
conflict with pharmacists’ business interests.
I think I have concerns about the INR [Interna-
tional Normalised Ratio] thing if it is not done in 
very close conjunction with the… if the pharmacist 
is brought in as part of the GP team then I think 
that’s fine but if it’s a standalone [service] and there 
isn’t much communication, then yes they’d be able 
to do it technically but the kind of information that 
might be lost…(GP#13, G1) [Speaking about collabo-
rative prescribing for patients taking warfarin]
Another possible threat to patient care voiced was 
that pharmacists were not trained in diagnosis 
and treatment. It was thought unsafe for pharma-
cists to give recommendations without appropri-
ate skills and training, based on assumptions, 
and with little clinical information. The majority 
of GPs would agree to share clinical notes with 
pharmacists providing that patients gave consent. 
However, many GPs preferred the information to 
stay within the GP’s surgery.
The GPs considered the major threats to their 
own work were time constraints and increased 
workloads (carrying out recommendations from 
pharmacists). Even though GPs thought pharma-
cist prescribing could potentially compete with 
GPs’ own work, they thought that it would not 
be a problem currently as there are shortages of 
doctors in NZ.
I don’t know if there’s anywhere in NZ where there 
are too many GPs, it might be seen as a turf war 
when there was not enough business… But I think 
New Zealand is under-provided with GPs and so, in 
general I think it [pharmacists’ medication-related 
services] would be welcomed. (GP#10, G1)
GPs were also concerned that they could be given 
extra work (e.g. reviewing pharmacists recom-
mendations) without remuneration. 
What worries me is that it will be time-consuming 
and not remunerated anyway. (GP#7, G2) 
Despite the possible threats, GPs thought they 
would be more accepting of the services if they 
knew the pharmacist well, or if they already had 
a good working relationship with them. GPs felt 
that it was essential for them to trust the phar-
macist in order to accept their new services.
Obviously sometimes we don’t make a careful deci-
sion… so I think that’s a more difficult area, because 
I think that’s almost where you actually need a phar-
macy facilitator on site, or at least in close relation-
ship. I’d probably accept it from her [local pharma-
cist] because I speak to her frequently and know her. 
I think it’s to do with the relationship. (GP#1, G3)
Discussion
The current study provides insight into GPs’ 
perspectives about pharmacists conducting 
medication review and prescribing. The analy-
sis was conducted by comparing the themes of 
GPs’ perceptions of their own contributions 
with their perceptions of pharmacists providing 
similar services. GPs perceived that their own 
skills and training were well suited to review-
ing and prescribing patients’ medications. GPs 
also described their heavy workloads and short 
consultation time as limitations of GPs’ services. 
GPs thought that pharmacists could mitigate GPs’ 
limitations in medication review, as they were 
perceived to be knowledgeable in pharmacology, 
more aware of drug interactions and would have a 
longer consultation time if funded by the health 
service to carry out the reviews. However, GPs 
had some concerns about pharmacist prescrib-
ing, as they believed that pharmacists lacked the 
appropriate skills and training in diagnosis and 
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1.  having positive outcomes41 
2. reducing GPs’ initial concerns and negative 
perceptions of pharmacists’ expertise and 
competence42,43 
3.  increasing GPs’ positive perceptions of 
pharmacists’ contributions to diagnosis, 
prescribing, monitoring and medication review 
over time,43 and 
4. reducing GPs’ workloads.37,42 
In those studies, close collaboration occurred as 
integration of the services into the GPs’ prac-
tice.42,43 Changes in GPs’ perceptions are reported 
to be influenced by the amount of experience 
that the GPs had of working alongside pharma-
cists.15,43 Close collaboration would facilitate more 
consistent interactions between GPs and phar-
Figure 1. Proposed New Zealand pharmacist prescribing scope of practice
Diagnosis
Doctor
Pharmacist
Choice of intervention
Set treatment goal, prescribe medications, prognosis
Optimise medications
Outcomes, events
Medication choice Refer Surgery Other
  Doctor prescribing scope of practice
  Proposed NZ pharmacist prescribing scope of practice
prescribing, and do not know patients’ clinical 
conditions well. On the other hand, GPs thought 
such pharmacist-led services could reduce GPs’ 
workloads and benefit patients, if appropriate 
‘controls’ were in place and co-location of those 
services occurred. 
Our findings were consistent with other studies:
1.  GPs’ acceptance of pharmacists’ contributions 
to clinical care and prescribing was 
underpinned by patient-safety issues;14,36 
2. Pharmacists need to be competent in 
prescribing37 and have good working 
relationships with the medical team;38 and 
3.  GPs’ perceived that pharmacist prescribing 
would include pharmacists making a 
diagnosis.14-16
A schematic diagram that summarises the au-
thors’ view of the pharmacist prescriber scope of 
practice outlined in the consultation document 
by the Pharmacy Council of New Zealand19 is 
presented in Figure 1. Pharmacist prescribing in 
NZ is being proposed as a collaborative model 
that requires joint practice between a pharmacist 
and a GP or GP practice group. In the proposed 
model, the pharmacist will prescribe (modify 
the medication therapy) to optimise medication-
related outcomes for patients who have a working 
diagnosis and a defined treatment goal.19 Modi-
fication of treatment goals, based on a changing 
clinical picture, would then provide feedback to 
the patient-care process initiated earlier by the 
GPs (diagnosis, and selection of treatment modal-
ity) and would not include pharmacists making 
a diagnosis.19 The proposed scope of practice is 
not intended to replace the patient’s need to see 
a doctor for diagnosis or treatment, or to cause 
discontinuation of care.39 The proposed model 
would suit pharmacists’ strengths in medication 
management, and doctors’ skills in diagnosis and 
disease management. Pharmacist prescribers also 
must have no financial interest in the dispensing 
of their own prescriptions.40 
GPs in the current study appeared to accept 
pharmacists’ clinical roles if performed in close 
collaboration with GPs. Close collaboration be-
tween pharmacists and GPs was reported in other 
studies as: 
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macists and help develop trust. It was reported 
that the integration of pharmacists’ services 
into the GP’s practice allowed GPs to recognise 
pharmacists’ expertise and clinical competence.43 
However understanding pharmacists’ roles could 
take some time as role negotiation and shifting 
are an implicit part of the process.42 
medication review and prescribing are based on 
GPs with limited experience of those services. 
In contrast to a previous study reporting GPs’ 
years of practice to be inversely related to their 
acceptance of pharmacists’ clinical services,24 the 
current study found no difference in percep-
tions between GPs with more (>20 years) or less 
(<20 years) clinical experience. In our study, 
both groups of GPs appeared to accept MUR and 
Clinical Medication Review services, although 
some resistance was found to pharmacist prescrib-
ing. Although saturation was achieved in G3, it is 
possible that GPs’ perceptions might be differ-
ent if they had had extensive experience with 
patients who had received MURs.
Furthermore, participants may have given a so-
cially desirable response despite the interviewer’s 
(EH) request to disregard her background in 
pharmacy. GPs in the current study might also 
already have a close working relationship with a 
local community pharmacist that could influence 
their perceptions of new services by pharmacists. 
Recall bias for GPs with MUR patients was also 
possible, as their patients had experienced the 
services up to five years previously. 
In conclusion, GPs felt that their own experi-
ence and skills suited them well for carrying out 
medication review and prescribing for patients, 
and that pharmacists had perceived strengths in 
areas where GPs had limitations, such as time 
and knowledge of pharmacology. However, GPs 
had some concern about the possible impact of 
pharmacist-led services on patients, GP prac-
tices and GP–patient relationships. GPs felt that 
there was a possibility of working together with 
pharmacists in providing those services if the 
appropriate controls (protocols, guidelines, close 
monitoring), close collaboration and co-location 
of the services occurred. 
Health professionals such as GPs and community 
pharmacists should not work in isolation but 
embrace the idea of working as a team, helping 
each other to provide the best care to patients.
The findings provide insight into some perceived 
potential benefits from GPs and pharmacists 
working together to provide patient care. How-
ever, this would need to be appropriately set up 
and supported by the health care system. Health 
professionals such as GPs and community pharma-
cists should not work in isolation but embrace the 
idea of working as a team, helping each other to 
provide the best care to patients. Since it has been 
reported that patients visit pharmacies more often 
than seeing their GPs, in order to improve patient 
care it is important that both professions have the 
same aims/treatment plans and that they share 
their information and expertise.44 These findings 
also provide insight into how patient-oriented care 
services in NZ might be improved. Lack of appro-
priate systems, funding and initiatives in the cur-
rent setting to foster close collaboration between 
health care professionals may limit the potential 
benefits of collaborative practice reaching patients. 
To improve this, future studies should explore the 
potential facilitators and barriers to collaborative 
health care practice in the health system. 
Although some GPs (G3) had patients who had 
experienced MUR services, the investigators 
could not identify any difference in perspectives 
when compared with GPs whose patients had not 
utilised MUR services. This might, in part, be 
due to the limited number of patients who had 
experienced the MUR services (between three 
and six patients per GP) in this GP cohort (G3). 
It should be noted that our interpretation of 
GPs’ perceptions of pharmacists’ contributions to 
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APPENDIX: Topic guide for the interviews
1.  Demographic information on the GP practice 
2. GP’s experience of working with pharmacists
3.  Views on new services provided/proposed for pharmacists, e.g. medication use review (MUR) and 
Clinical Medication Review
4. Views on pharmacists having access to a patient’s clinical notes
5.  Views on pharmacists prescribing medications in general
6. Views on pharmacist prescribers at the GP’s practice
7.  Perceived impact that the services/proposed services might have on GP’s practice
8. Views on what could be improved between GPs and pharmacists when providing patient care